As at January 28, 2022Show prices
SASKATOON, Saskatchewan–(BUSINESS WIRE)–
CanniMed Therapeutics Inc. (TSX: CMED) (“CMED” or the “Company”), announces, in accordance with the Toronto Stock Exchange requirements, the voting results from its Annual General Meeting held Wednesday, April 19, 2017 in Saskatoon, Saskatchewan.
A total of 10,687,411 common shares were voted at the meeting by proxy, representing 47.52% of the votes attached to all outstanding shares. Shareholders voted in support of all items of business, including the election of all director nominees as follows:
Per cent of
Per cent of
|Dwayne L. Lashyn||10,465,538||99.95%||5,025||0.05%|
|Bruce F. Mackler||10,465,338||99.95%||2,225||0.05%|
|Brandon P. Price||9,699,691||99.95%||5,000||0.05%|
The Company also confirmed that shareholders approved the appointment of Deloitte LLP (“Deloitte”)
About CanniMed Therapeutics Inc.
The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
CanniMed Ltd., through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.